Menopause & HRT Nursing Guide

Menopause — Definition & Stages

Menopause is defined as 12 consecutive months of amenorrhoea without another cause, reflecting permanent cessation of ovarian follicular activity. Mean age of natural menopause: 51 years (range 45–55).

Perimenopause

Period of irregular cycles leading up to final menstrual period
Begins with hormonal fluctuation — FSH rises, oestradiol erratic
Duration: 4–8 years on average
Symptoms may be more severe than post-menopause phase due to oestrogen fluctuation
Diagnosis is clinical — hormonal testing often unhelpful in this phase

Post-Menopause

Confirmed after 12 months amenorrhoea (>age 45)
FSH persistently elevated (>30 IU/L), oestradiol low
Symptoms continue and new long-term health risks emerge
NICE NG23: diagnose menopause clinically in women >45 with symptoms — no blood tests needed

Premature Ovarian Insufficiency (POI)

Menopause before age 40. Affects ~1% of women.

Diagnostic Criteria

FSH >25 IU/L on 2 occasions at least 4 weeks apart
Oligo/amenorrhoea for ≥4 months
Age <40 years

Management

HRT recommended until age 51 — replaces natural oestrogen production, not optional
Higher doses may be required than standard menopausal HRT
OCP is an alternative but does not fully replicate physiological oestrogen

Surgical Menopause

Bilateral oophorectomy causes immediate menopause regardless of age.

Symptoms onset within 24–48 hours — often more severe than natural menopause
Abrupt loss of oestrogen and testosterone
HRT should be started immediately post-operatively unless contraindicated
Women <45: same guidance as POI — HRT until at least age 51
Hysterectomy without oophorectomy: ovarian function preserved — menopause timing unchanged but diagnosis requires FSH (no menstruation to track)

Hormonal Interpretation

Test	Menopausal Range	Clinical Significance
FSH	>30 IU/L (post-menopause)	Pituitary response to low oestrogen; elevated in POI (>25 IU/L x2)
LH	Elevated (ratio FSH:LH may change)	Less diagnostically specific than FSH alone
Oestradiol (E2)	<100 pmol/L post-menopause	Low E2 + high FSH = confirms menopause
AMH	Very low/undetectable	Ovarian reserve marker — useful in POI workup
Thyroid (TSH/T4)	Normal unless thyroid disease	Exclude hypothyroidism (overlapping symptoms)

NICE NG23: FSH testing is not required for diagnosis in women >45 with typical symptoms. Testing useful <45 (perimenopause) and <40 (POI investigation).

Assessment Tools

Greene Climacteric Scale

21-item validated questionnaire
Domains: psychological, somatic, vasomotor, sexual
Scored 0–3 per item — total and subscale scores
Widely used in research and clinical monitoring
Tracks treatment response over time

Menopause Rating Scale (MRS)

11 symptoms across 3 subscales: somatic, psychological, urogenital
Self-administered, validated in multiple languages
Scores indicate severity: none/mild/moderate/severe/very severe
Available in Arabic — relevant for GCC clinical practice
Useful for audit and treatment outcome measurement

NICE NG23 Key Recommendations (2015, updated 2023)

Diagnose perimenopause/menopause clinically in women ≥45 with symptoms
Offer HRT to treat menopausal symptoms after discussing benefits and risks
Do not use progestogen-only pill (POP) or Mirena IUS alone as HRT (though Mirena can be the progestogen component)
No arbitrary time limit on HRT duration — annual review recommended
Transdermal route preferred for women with increased VTE/cardiovascular risk
Testosterone may be offered for low libido not responding to HRT
CBT recommended for mood changes and vasomotor symptoms

Vasomotor Symptoms

Hot Flushes

Affect ~75–80% of menopausal women
Sudden sensation of intense heat — face, neck, chest
Last 2–4 minutes; may occur >10x/day (severe)
Triggered by: warm environments, caffeine, alcohol, spicy food, stress

Severity Grading

Mild <7 per week, no sleep disruption
Moderate 7–14/week, some sleep disruption
Severe >14/week or significant QoL impairment

Night Sweats

Nocturnal hot flushes causing drenching sweats
Major driver of insomnia and fatigue
Cumulative sleep debt — significant QoL impact
Associated with increased cardiovascular risk (poor sleep)

Nursing Actions

Document frequency, severity, duration, triggers
Use validated tool (MRS/Greene) at each review
Assess impact on work, relationships, mental health
Offer treatment — HRT most effective (>80% reduction)

Genitourinary Syndrome of Menopause (GSM)

Umbrella term replacing "vaginal atrophy" — encompasses all vulvovaginal and urinary effects of oestrogen deficiency.

Vaginal Symptoms

Dryness, itching, burning
Dyspareunia (painful intercourse)
Vaginal pH rises (>5)
Recurrent BV/Candida

Urinary Symptoms

Urgency/frequency
Dysuria
Recurrent UTIs
Stress urinary incontinence

Sexual Impact

Reduced libido
Reduced arousal/lubrication
Anorgasmia
Relationship strain

Key Point: Topical oestrogen (cream, pessary, ring) is safe for long-term use — systemic absorption is minimal and does not require concurrent progestogen. Safe even in women with breast cancer history (per NICE NG23 2023 — discuss with oncologist).

Psychological Symptoms

Mood changes: irritability, low mood, anxiety — may mimic depression
Brain fog: poor concentration, word-finding difficulty, memory lapses
Low libido (testosterone also declines in perimenopause)
Loss of confidence: work performance anxiety
Distinguish from primary depression/anxiety disorder — timing relative to cycle/amenorrhoea is key
HRT can significantly improve mood — acts before antidepressants in menopausal context
CBT effective for psychological symptoms (NICE recommended)

Musculoskeletal & Other

Musculoskeletal

Joint pains and stiffness (arthralgia)
Myalgia — generalised muscle aches
Carpal tunnel syndrome more common
HRT reduces musculoskeletal symptoms

Skin & Hair

Collagen loss — skin thinning, dryness, reduced elasticity
Hair thinning (androgenic alopecia)
Formication (crawling skin sensation)

Sleep

Insomnia — onset and maintenance
REM disruption
Compound effect with night sweats

Cardiovascular Risk Post-Menopause

Oestrogen loss accelerates cardiovascular risk. Women's CVD risk approaches that of men within 10 years of menopause.

LDL cholesterol rises, HDL falls
Blood pressure increases
Central adiposity (visceral fat) increases
Insulin resistance increases
Endothelial function impaired
HRT started <60 or within 10 years of menopause may have cardioprotective effects ("timing hypothesis" / "window of opportunity")

Osteoporosis — Post-Menopausal Bone Loss

Oestrogen is critical for bone remodelling. Post-menopause: bone loss 2–3% per year for the first 5–10 years.

Risk Factors

Early menopause / POI
Smoking, alcohol >3 units/day
Low BMI, prolonged amenorrhoea
Corticosteroid use >3 months
Family history of hip fracture
Low calcium/vitamin D (very common in GCC)
Sedentary lifestyle, immobility

T-Score Interpretation (DEXA)

T-Score	Classification
> -1.0	Normal bone density
-1.0 to -2.5	Osteopenia
< -2.5	Osteoporosis
< -2.5 + fracture	Severe osteoporosis

DEXA Scan Indications & T-Score Guide ▼

DEXA Scan Indications

POI or early menopause (<45) — baseline at diagnosis
Menopause <40 — DEXA at diagnosis and every 2–3 years if not on HRT
Fragility fracture (low-trauma)
Prolonged corticosteroid use (>3 months equivalent ≥5mg prednisolone/day)
BMI <19 kg/m²
Conditions associated with bone loss: RA, IBD, coeliac, hyperparathyroidism
Strong family history of osteoporosis/hip fracture
Amenorrhoea >6 months before age 40 (not POI)
Use FRAX tool to calculate 10-year fracture risk — guides intervention threshold

Intervention Thresholds

T-score < -2.5: bisphosphonate indicated (alendronate first line)
T-score -1.0 to -2.5 with high FRAX risk: consider bisphosphonate
All women: calcium 700mg + Vitamin D 400–800 IU daily (especially GCC context)
HRT maintains and may increase bone density — protective effect ceases on cessation
Repeat DEXA: after 2 years of treatment, then every 2–5 years

HRT Types — Choosing the Right Regimen

Hysterectomy (No Uterus)

Oestrogen-only HRT

No risk of endometrial hyperplasia — progestogen NOT needed
Safer breast cancer risk profile than combined HRT
All routes: oral, transdermal, implant

Intact Uterus

Combined Oestrogen + Progestogen

Progestogen essential to protect endometrium
Sequential (cyclical): for perimenopause — monthly bleed
Continuous combined: for post-menopause — no bleed (amenorrhoeic)
Mirena IUS can serve as progestogen component

HRT Formulations & Routes

Route	Examples	Advantages	Considerations
Oral	Elleste Solo, Premarin, Utrogestan (oral progesterone)	Convenient, established evidence base	First-pass hepatic metabolism — higher VTE/stroke risk than transdermal
Transdermal Patch	Evorel, Estradot, FemSeven	Avoids first-pass — lower VTE/stroke risk; consistent levels	Skin irritation; patch changes 1–2x/week
Transdermal Gel	Oestrogel, Sandrena	Flexible dosing; skin absorption; lower VTE risk	Daily application; avoid skin contact with others
Nasal Spray	Aerodiol	Rapid absorption; transmucosal — avoids first pass	Less commonly used; daily dosing
Vaginal (local)	Vagifem, Ovestin, Estring ring	Treats GSM; minimal systemic absorption; no progestogen needed	Does not treat systemic symptoms (flushes, mood)
Implant	Oestradiol pellet (subcutaneous)	6-monthly; consistent levels; testosterone available	Requires procedure; tachyphylaxis possible

Transdermal preferred for: BMI >30, migraine with/without aura, previous DVT/PE, cardiovascular disease, diabetes, hypertriglyceridaemia.

Progestogens — Important Differences

Micronised Progesterone (Utrogestan)

Body-identical — same molecule as endogenous progesterone
Lowest breast cancer risk of any progestogen (Fournier 2008 E3N cohort)
Favourable cardiovascular profile — no adverse lipid effects
Sedating effect — oral use at night may aid sleep
Can be used vaginally (reduces systemic effects)
NICE NG23 2023: preferred progestogen

Synthetic Progestogens (Progestins)

MPA (medroxyprogesterone acetate) — used in WHI study — associated with increased breast cancer risk
Norethisterone — androgenic effects; less favourable profile
Levonorgestrel (Mirena IUS) — local endometrial action — minimal systemic effects
Dydrogesterone — intermediate profile
Progestogen component drives most HRT-associated risks

Duration of HRT — NICE NG23 Position

There is no arbitrary 5-year limit on HRT duration per NICE NG23 (2023). Benefits outweigh risks for most women who need it, and duration should be individualised with annual review.

Annual review: reassess symptoms, benefits, risks, patient preference
Benefits: symptom relief, bone protection, reduced cardiovascular risk (if started early), reduced diabetes risk, improved QoL
Risks: small increased breast cancer risk with combined HRT (similar to 1 glass wine/day or being overweight); oestrogen-only has minimal breast cancer risk increase
The absolute risk increase for breast cancer with <5 years combined HRT: ~5 extra cases per 1000 women
Stopping HRT: symptoms often return; bone protection reverses; gradual weaning may reduce rebound symptoms

HRT Contraindications

Absolute Contraindications (HRT should NOT be used):

Unexplained vaginal bleeding — investigate first
Oestrogen-sensitive cancer: breast cancer (current/recent — relative; discuss with oncologist for topical oestrogen), endometrial cancer (stage-dependent)
Uncontrolled hypertension (treat to target first, then reassess)
Active liver disease (deranged LFTs, acute hepatitis, cirrhosis)
Personal history DVT/PE without thrombophilia — use transdermal (not absolute for transdermal; oral is contraindicated)
Active or recent arterial thromboembolic disease (MI, stroke within 3–6 months)
Pregnancy (must exclude before starting)

Cautions (use with care/specialist input): migraine with aura (use transdermal), controlled hypertension, diabetes, fibroid uterus, gallbladder disease, SLE, otosclerosis.

WHI Study Re-appraisal & MHT Safety

The 2002 WHI study created widespread HRT fear — but its findings applied to a specific population (mean age 63, 10+ years post-menopause, using oral conjugated equine oestrogen + MPA) that does not represent typical HRT candidates.

Current Evidence Summary

Women <60 years or within 10 years of menopause: benefits clearly outweigh risks
Transdermal oestrogen + micronised progesterone: most favourable risk profile available
Breast cancer risk: mainly driven by progestogen type and duration; lower with body-identical progesterone
Cardiovascular: no increased risk with transdermal; possible benefit if started early ("timing hypothesis")
All-cause mortality: meta-analyses show possible reduction in women starting HRT <60

Non-Hormonal Options for Vasomotor Symptoms

SSRIs / SNRIs

Venlafaxine 37.5–75mg — most evidence; ~50–60% reduction in flush frequency
Paroxetine 10–20mg — licensed in USA for vasomotor symptoms
Escitalopram, Citalopram — evidence of modest benefit
Fluoxetine — less effective than other SSRIs
Dual benefit if co-existing depression/anxiety

AVOID paroxetine and fluoxetine in women on tamoxifen — CYP2D6 inhibition reduces tamoxifen efficacy (increases recurrence risk).

Other Pharmacological Options

Clonidine (alpha-2 agonist) — modest efficacy (~20–30%); SE: dry mouth, drowsiness, hypotension
Oxybutynin 2.5–5mg — anticholinergic; ~30% reduction in flush frequency; SE: dry mouth, constipation, cognitive effects (caution >65)
Gabapentin 300mg TDS — modest benefit; SE: sedation, dizziness — useful if co-existing pain/insomnia
Fezolinetant (Veoza) — NK3 receptor antagonist; NEW 2023 non-hormonal; significant reduction in moderate-severe flushes; NICE approved; first targeted non-hormonal
Stellate ganglion block — interventional; emerging evidence

Psychological & Behavioural Interventions

CBT (Cognitive Behavioural Therapy)

NICE NG23 recommended for mood changes and vasomotor symptoms
Hunter & Liao CBT model: targets hot flush beliefs and behaviours
Group or individual format — 4–8 sessions
Menopause Support app (NHS-endorsed) — digital CBT
Balance app — information + symptom tracker
Reduces flush frequency and impact by ~50% in studies

Lifestyle Modifications

Exercise: aerobic + resistance training — reduces flushes, improves mood, protects bone/heart
Cooling strategies: fan, cool spray, cool bedding (wool or bamboo), layered clothing
Trigger avoidance: caffeine, alcohol, spicy food, warm rooms
Weight management: adipose tissue produces oestrone — higher BMI = more severe flushes paradoxically in some studies
Mindfulness/yoga: emerging evidence for QoL improvement
Smoking cessation: smokers have earlier menopause and worse symptoms

GSM — Topical Oestrogen Guide & Non-Hormonal Alternatives ▼

Topical Oestrogen Products

Product	Type	Frequency
Vagifem 10mcg	Pessary	Daily x2 weeks, then 2x/week
Imvaggis (estriol)	Pessary	Daily x3 weeks, then 2x/week
Ovestin cream	Cream	Daily x3 weeks, then 2x/week
Estring	Vaginal ring	Replace every 90 days
Intrarosa (DHEA)	Pessary	Daily — converts to oestrogen + androgen locally

Systemic absorption minimal — safe long-term. No progestogen required. Safe in most breast cancer survivors (discuss with oncologist).

Non-Hormonal Vaginal Options

Hyaluronic acid pessaries/gel — hydrates vaginal mucosa; comparable to low-dose oestrogen for dryness in some trials
Replens (polycarbophil) — vaginal moisturiser; 2–3x/week; restores pH and moisture
YES VM (water-based moisturiser) — organic option
Lubricants: YES WB, Sylk — for intercourse; not moisturisers (temporary)
Avoid petroleum-based products (Vaseline) — disrupt vaginal flora, degrade condoms
Pelvic floor physiotherapy — improves urinary symptoms and sexual function

Bone Protection — Non-HRT Options

Supplements

Calcium: 700mg/day dietary target; supplement only if dietary intake inadequate (<500mg/day from food)
Vitamin D: 400–800 IU daily; higher doses (1000–2000 IU) for deficiency — critically important in GCC
Combined calcium + vitamin D: reduces fracture risk in elderly
Magnesium: cofactor for vitamin D metabolism
Vitamin K2: emerging role in bone mineralisation

Pharmacological

Alendronate 70mg weekly (bisphosphonate) — first-line; reduces fractures by 40–50%
Risedronate — alternative bisphosphonate (better GI tolerance)
Denosumab (Prolia) — 6-monthly SC injection; antiresorptive; used if bisphosphonate intolerant
Raloxifene (SERM) — for spinal osteoporosis; reduces breast cancer risk; does NOT help flushes (may worsen)
Zoledronic acid — annual IV infusion; severe osteoporosis
Weight-bearing exercise — essential alongside pharmacotherapy

Premature Ovarian Insufficiency (POI) — Overview

POI is not simply "early menopause" — it is a complex condition with profound health, fertility and psychological consequences. Diagnosis before age 40 requires systematic investigation.

Causes

Idiopathic: 50% — no cause identified after full investigation
Autoimmune: adrenal antibodies (anti-21-hydroxylase) — 4%; associated with Addison's, hypothyroidism, type 1 DM, vitiligo
Chromosomal: Turner syndrome (45X0); Fragile X premutation (FMR1 — test all POI); other X-chromosome anomalies
Iatrogenic: chemotherapy (alkylating agents highest risk — cyclophosphamide), radiotherapy to pelvis, bilateral oophorectomy
Infectious: mumps oophoritis (rare)
Genetic: BRCA2 carriers higher POI risk

Diagnosis Pathway

FSH >25 IU/L on 2 occasions ≥4 weeks apart
Irregular/absent periods ≥4 months
Age <40 years

Investigation Screen

Repeat FSH/LH/oestradiol + AMH
Karyotype (Turner/X abnormalities)
FMR1 premutation (Fragile X)
Adrenal antibodies (anti-21-hydroxylase)
Thyroid antibodies + TSH
Fasting glucose / HbA1c
DEXA scan at diagnosis
Pelvic USS (uterus/ovarian volume)

POI Diagnosis & Management Pathway ▼

Management Principles

HRT (or COCP) mandatory until at least age 51 — not optional; replaces missing oestrogen
Doses may need to be higher than standard menopausal HRT
Transdermal oestrogen preferred for long-term cardiovascular and bone protection
Progestogen if uterus intact; oestrogen-only if hysterectomy
Testosterone: consider for low libido if HRT insufficient
DEXA at diagnosis, repeat 2-yearly if not on HRT
Annual review: symptoms, bone, cardiovascular, thyroid/adrenal screen
Refer to specialist POI clinic for complex cases

Fertility Considerations

Intermittent spontaneous ovulation in 5–10% — pregnancies do occur
Contraception still needed if pregnancy is not desired (HRT is NOT contraceptive)
Egg donation: most successful fertility option — counsel early
Embryo/oocyte cryopreservation: discuss BEFORE iatrogenic POI (chemo/RT/surgery)
Refer to reproductive medicine for fertility counselling

GCC Autoimmune Screen

Autoimmune POI associated with: Addison's disease, Hashimoto's thyroiditis, type 1 DM, coeliac, vitiligo
Annual fasting glucose, TSH, adrenal screen recommended
Addison's crisis risk — carry steroid emergency card if confirmed

Health Consequences of Untreated POI

Cardiovascular

2–3x increased CVD risk vs age-matched women
Accelerated atherosclerosis
HRT largely normalises risk if started early

Bone

Rapid bone loss from time of POI onset
High lifetime fracture risk if untreated
HRT most effective bone protection in this age group

Cognitive

Increased risk of dementia if POI untreated
Oestrogen neuroprotective in younger brain
Cognitive decline accelerated without HRT

Psychological Impact of POI

Grief response: loss of reproductive identity, future family planning
Shock and disbelief: often long diagnostic delay (mean 6 years) — frustration and anger
Relationship impact: sexual dysfunction, partner communication challenges
Workplace: symptoms affecting concentration, mood, physical capacity
Cultural context in GCC: fertility strongly linked to female identity — POI may be devastating and poorly understood culturally
Refer for psychological support — CBT, counselling, peer support
Daisy Network (UK POI charity) — international reach; peer support groups; patient information
Screen for depression and anxiety at each review — PHQ-9 / GAD-7

Menopause in Arab Women — Cultural Context

Cultural Attitudes

Cultural silence: menopause often not discussed openly — "change of life" may be a taboo subject within families
Older Arabic women may not present with symptoms — stoicism, normalising, not wanting to be a burden
Some GCC women may perceive menopause positively — freedom from menstruation, pregnancy, and associated restrictions (e.g., prayer, fasting, intimate relations during Ramadan)
Husband/family involvement in healthcare decisions — may affect HRT discussions
Modesty considerations affect examination willingness
Language barriers — use validated Arabic assessment tools

Nursing Considerations

Allow female-only clinical encounters where preferred
Use Arabic MRS / validated Arabic menopause questionnaires
Explore cultural beliefs about HRT — hormones may be viewed with suspicion
Discuss HRT safety in culturally sensitive language
Involve family only with explicit patient consent
Frame treatment in terms of long-term health, not just symptom relief
Be aware of fasting (Ramadan) — adjust dosing schedules; transdermal unaffected by fasting
Validate positive aspects of the transition while addressing health risks

Herbal Remedies & Complementary Approaches — GCC Use

Herbal remedies are widely used in GCC countries. Nurses must ask about all herbal/traditional products at every consultation — interactions and safety concerns exist.

Remedy	GCC Use	Evidence	Safety with HRT
Black Seed (Nigella sativa)	Very common — general health tonic	Limited evidence for menopausal symptoms; anti-inflammatory properties	May affect CYP enzymes — theoretical interaction; generally considered safe in moderate doses
Fenugreek (Hilba)	Hot flushes, libido	Phytoestrogenic activity; small trials show some benefit for libido/dryness	Phytoestrogen — theoretical additive oestrogenic effect; caution in oestrogen-sensitive cancers
Sage	Night sweats, hot flushes	Modest RCT evidence for flush reduction	Generally safe; avoid high medicinal doses if on anticoagulants
Phytoestrogens (soy/red clover)	Diet and supplements	Modest benefit for mild symptoms; less effective than HRT	Theoretically additive — caution in oestrogen-sensitive cancer
Zamzam/zamzam water	General wellbeing	No clinical evidence for menopausal symptoms	Safe
Frankincense (Boswellia)	Joint pain, wellbeing	Anti-inflammatory; some evidence for joint pain	Generally safe with HRT

Vitamin D Deficiency in GCC — Post-Menopausal Bone Risk

Vitamin D deficiency is endemic in GCC countries — a combination of factors creates high-risk post-menopausal population.

Risk Factors (GCC-Specific)

Indoor lifestyle: extreme heat discourages outdoor activity — minimal sun exposure
Full body covering (hijab/abaya/niqab): further reduces cutaneous vitamin D synthesis
Skin pigmentation: darker skin requires longer sun exposure for equivalent synthesis
Low dietary dairy intake in some communities
Cultural preference for indoor leisure activities
Postmenopausal oestrogen loss compounds bone risk on top of pre-existing VitD deficiency

Nursing Actions

Screen vitamin D (25-OH) routinely at menopause assessment
Treat deficiency: loading dose 50,000 IU weekly x8–12 weeks, then maintenance 2000 IU daily
Maintenance for all post-menopausal women in GCC: 1000–2000 IU daily
Calcium from diet preferred — supplement only if dietary intake insufficient
Consider weight-bearing exercise prescription (dawn/dusk outdoor walk)
DEXA scan more readily indicated in GCC post-menopausal women given vitamin D deficiency prevalence

GCC Regulatory & Professional Framework

SCFHS (Saudi Arabia)

SCFHS classification: nursing specialties include women's health/midwifery
Gynaecology and menopause management included in advanced nursing practice competencies
Nurse practitioner scope: assessment, investigation, initiating HRT under protocol
Continuing education requirements: women's health CPD for renewal

DOH Abu Dhabi / MOH UAE

Women's health nursing competency frameworks include menopause care
Nurse-led menopause clinics developing in tertiary centres
Emirati women's health programs — national screening initiatives

DHA (Dubai)

DHA Women's Health Guidelines align with NICE recommendations adapted for GCC context
Registered nurses in women's health: competence in menopause symptom assessment, counselling, referral
HRT prescribing: physician role in DHA/UAE; nurse initiates counselling and monitoring

Arabic Assessment Tools

Menopause Rating Scale (MRS) — validated Arabic version available
Arabic version Menopause-Specific Quality of Life (MENQOL) questionnaire
Arabic Greene Climacteric Scale adaptation (research use)
Use validated tools — not direct translation of English tools

GCC Context — 5 Exam MCQs

Click an option to reveal whether it is correct and view the explanation.

1. A 38-year-old UAE national woman presents with 6 months of irregular periods and hot flushes. Her FSH is 32 IU/L. Which investigation is most important to confirm the diagnosis of POI?

A. Pelvic ultrasound to assess ovarian volume

B. Repeat FSH in 4–6 weeks

C. Thyroid function tests

D. Endometrial biopsy

POI requires FSH >25 IU/L on TWO occasions at least 4 weeks apart. A single elevated FSH is insufficient for diagnosis. All other investigations are part of the workup but not the confirmatory step.

2. A 52-year-old Saudi woman with an intact uterus is started on transdermal oestrogen for menopausal symptoms. She asks why she needs a "second hormone". Which is the best explanation?

A. Progestogen helps reduce hot flushes more than oestrogen alone

B. Progestogen reduces the risk of breast cancer caused by oestrogen

C. Oestrogen alone stimulates the uterine lining; progestogen protects against endometrial hyperplasia and cancer

D. Progestogen provides contraception while on HRT

In women with an intact uterus, oestrogen-only HRT causes endometrial proliferation and increases endometrial cancer risk. Progestogen (or Mirena IUS) is added to protect the endometrium. It does not reduce breast cancer risk — if anything, synthetic progestogens may modestly increase it.

3. A nurse in Abu Dhabi is counselling a 56-year-old Emirati woman with severe hot flushes who declines HRT due to fear of breast cancer. She has no contraindications. Which non-hormonal medication has the BEST evidence for moderate-severe vasomotor symptoms and is newly approved?

A. Clonidine 75 mcg twice daily

B. Gabapentin 300mg three times daily

C. Fezolinetant (NK3 receptor antagonist)

D. Evening primrose oil

Fezolinetant (Veoza) is a neurokinin-3 (NK3) receptor antagonist approved in 2023. It is the first targeted non-hormonal treatment for moderate-severe vasomotor symptoms. It acts centrally to reduce the KNDy neuron dysregulation that drives hot flushes. Clonidine and gabapentin have limited and weaker evidence.

4. Regarding vitamin D and post-menopausal bone health in GCC, which statement is MOST accurate?

A. GCC women have lower rates of vitamin D deficiency than European women due to sun exposure

B. Vitamin D deficiency has no impact on fracture risk if calcium intake is adequate

C. Indoor lifestyle, full body covering and skin pigmentation compound post-menopausal bone loss risk in GCC women

D. Bisphosphonates should be started in all post-menopausal GCC women regardless of DEXA result

Vitamin D deficiency is highly prevalent in GCC countries despite the sunny climate, due to indoor lifestyle, full body covering (abaya/hijab/niqab), and skin pigmentation reducing cutaneous synthesis. This significantly compounds post-menopausal bone loss from oestrogen deficiency. Bisphosphonates are indicated only when T-score <-2.5 or high FRAX risk — not universally.

5. A 49-year-old woman taking tamoxifen for breast cancer history asks about treatment for her severe hot flushes. She specifically asks about SSRIs. Which is the most appropriate nursing response?

A. All SSRIs are equally effective and safe with tamoxifen

B. SSRIs are contraindicated in breast cancer survivors regardless of type

C. Venlafaxine or escitalopram are preferred — paroxetine and fluoxetine must be avoided as they inhibit CYP2D6 and reduce tamoxifen efficacy

D. Recommend fezolinetant first as it has no drug interactions

Paroxetine and fluoxetine are potent CYP2D6 inhibitors. Tamoxifen is a prodrug converted to its active form (endoxifen) by CYP2D6. Inhibition reduces endoxifen levels by up to 70%, potentially increasing breast cancer recurrence risk. Venlafaxine, citalopram, and escitalopram are weak CYP2D6 inhibitors and are safe alternatives. Fezolinetant may also be considered but venlafaxine has the strongest evidence for hot flushes.

Additional GCC Exam Practice MCQs

Supplementary questions for SCFHS / DHA / DOH exam preparation. Click an option to reveal the answer.

6. According to NICE NG23, at what age can menopause be diagnosed clinically WITHOUT requiring FSH blood tests?

A. ≥40 years with symptoms

B. ≥45 years with typical menopausal symptoms

C. ≥50 years regardless of symptoms

D. Any age if FSH is elevated

NICE NG23 states that in women aged 45 and over presenting with typical menopausal symptoms, the diagnosis can be made clinically without the need for FSH blood testing. Testing is recommended for women aged 40–45 with symptoms (perimenopause) and is required for POI diagnosis in women under 40.

7. A 45-year-old woman with a BMI of 33 and a history of migraine with aura wants to start HRT. Which route of oestrogen administration is most appropriate?

A. Oral oestrogen tablets daily

B. Transdermal patch or gel

C. Subcutaneous implant

D. Vaginal oestrogen ring

Transdermal oestrogen (patch or gel) is preferred for women with BMI >30 and/or migraine (with or without aura). Oral oestrogen undergoes first-pass hepatic metabolism, increasing clotting factors and VTE risk. Transdermal bypasses this mechanism, maintaining a much lower VTE and stroke risk. The vaginal ring only treats local GSM symptoms and would not address systemic symptoms.

8. Genitourinary syndrome of menopause (GSM) includes which combination of symptoms?

A. Hot flushes, night sweats, vaginal dryness

B. Joint pains, mood changes, urinary urgency

C. Vaginal dryness, dyspareunia, urinary urgency, recurrent UTIs

D. Brain fog, low libido, insomnia

GSM is the umbrella term for all urogenital effects of oestrogen deficiency: vaginal dryness, burning, dyspareunia, urinary urgency, frequency, dysuria, and recurrent UTIs. It does not include vasomotor symptoms (hot flushes/night sweats) which are a separate symptom category. Topical oestrogen is the most effective treatment for GSM.

9. Which progestogen has the most favourable safety profile regarding breast cancer risk when used as part of combined HRT?

A. Medroxyprogesterone acetate (MPA)

B. Micronised progesterone (Utrogestan)

C. Norethisterone

D. Levonorgestrel oral

Micronised progesterone (Utrogestan) is body-identical — chemically identical to endogenous progesterone. The E3N cohort study (Fournier 2008) and subsequent data show it has the lowest breast cancer risk of any progestogen. MPA (used in the WHI study) and norethisterone (androgenic) have less favourable profiles. NICE NG23 2023 recommends micronised progesterone as the preferred progestogen.

10. A post-menopausal Emirati woman using black seed (Nigella sativa) oil daily asks if she can start topical vaginal oestrogen for GSM. What is the most appropriate nursing response?

A. Black seed is contraindicated with any form of oestrogen therapy

B. She must stop the black seed before starting topical oestrogen

C. Topical vaginal oestrogen has minimal systemic absorption; document the herbal use and proceed — advise moderation and watch for symptoms; refer to prescriber for final decision

D. Black seed has strong evidence for GSM so topical oestrogen is unnecessary

Topical vaginal oestrogen has minimal systemic absorption and is generally very safe. Black seed (Nigella sativa) has theoretical CYP enzyme interactions but is generally considered safe in moderate dietary/culinary amounts. The nurse should document all herbal remedies, provide evidence-based counselling, advise against high medicinal doses, and flag to the prescriber — not categorically refuse treatment. Black seed has no strong evidence for GSM and is not a substitute for topical oestrogen.